Summary
475.98 -11.23(-2.30%)07/01/2024
Idexx Laboratories, Inc. (IDXX)
Idexx Laboratories, Inc. (IDXX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.30 | -1.71 | -3.57 | -9.81 | -12.61 | -0.89 | 76.87 | 51,415.21 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 475.98 | |
| Open | 486.44 | |
| High | 490.70 | |
| Low | 475.63 | |
| Volume | 181,441 | |
| Change | -11.23 | |
| Change % | -2.30 | |
| Avg Volume (20 Days) | 384,499 | |
| Volume/Avg Volume (20 Days) Ratio | 0.47 | |
| 52 Week Range | 372.50 - 583.39 | |
| Price vs 52 Week High | -18.41% | |
| Price vs 52 Week Low | 27.78% | |
| Range | -1.37 | |
| Gap Up/Down | -0.07 | |
Fundamentals | ||
| Market Capitalization (Mln) | 40,237 | |
| EBIDTA | 1,232,167,936 | |
| PE Ratio | 49.4971 | |
| PEG Ratio | 4.7534 | |
| WallStreet Target Price | 578.84 | |
| Book Value | 18.9310 | |
| Earnings Per Share | 10.3000 | |
| EPS Estimate Current Quarter | 2.6700 | |
| EPS Estimate Next Quarter | 2.9900 | |
| EPS Estimate Current Year | 11.0300 | |
| EPS Estimate Next Year | 12.5700 | |
| Diluted EPS (TTM) | 10.3000 | |
| Revenues | ||
| Profit Marging | 0.2326 | |
| Operating Marging (TTM) | 0.3101 | |
| Return on asset (TTM) | 0.2263 | |
| Return on equity (TTM) | 0.7191 | |
| Revenue TTM | 3,724,852,992 | |
| Revenue per share TTM | 44.8280 | |
| Quarterly Revenue Growth (YOY) | 0.0710 | |
| Quarterly Earnings Growth (YOY) | 0.1020 | |
| Gross Profit (TTM) | 2,004,338,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 49.4971 | |
| Forward PE | 45.6621 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 27.8496 | |
| Revenue Enterprise Value | 11.4607 | |
| EBITDA Enterprise Value | 34.4569 | |
| Shares | ||
| Shares Outstanding | 82,587,296 | |
| Shares Float | 81,681,345 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.93 | |
| Institutions (%) | 93.08 | |
06/28 17:37 EST - seekingalpha.com
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing rapid growth and innovation in a high-growth market. Despite a lofty valuation, IDEXX's strong financials, consistent revenue growth, and long-term growth prospects justify a Buy rating.
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing rapid growth and innovation in a high-growth market. Despite a lofty valuation, IDEXX's strong financials, consistent revenue growth, and long-term growth prospects justify a Buy rating.
06/24 11:00 EST - businesswire.com
IDEXX Laboratories to Release 2024 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2024 Earnings Snapshot through a link on the IDEXX website, www.i.
IDEXX Laboratories to Release 2024 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2024 Earnings Snapshot through a link on the IDEXX website, www.i.
06/21 12:41 EST - zacks.com
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
06/06 09:55 EST - zacks.com
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
06/04 07:00 EST - prnewswire.com
IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes WESTBROOK, Maine , June 4, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes.
IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes WESTBROOK, Maine , June 4, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes.
05/31 12:36 EST - zacks.com
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
05/25 15:00 EST - investorplace.com
Barking Up the Right Tree: 3 Top Pet Stocks With ‘Pawsitive' Returns
The modern pet industry is a testament to the amounts that pet owners and animal lovers are willing to spend on their furry companions. In 2023, U.S. consumers alone spent $147 billion in the pet industry.
Barking Up the Right Tree: 3 Top Pet Stocks With ‘Pawsitive' Returns
The modern pet industry is a testament to the amounts that pet owners and animal lovers are willing to spend on their furry companions. In 2023, U.S. consumers alone spent $147 billion in the pet industry.
05/20 00:00 EST - https://www.zacks.com
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
IDEXX Laboratories' (IDXX Quick QuoteIDXX - Free Report) business has been suffering due to complex macroeconomic conditions and unfavorable currency movement. The stock carries a Zacks Rank #4 (Sell) currently.Global macroeconomic conditions, including growing geopolitical complexities, supply chain disruptions leading to increases in the unit cost of raw materials, shortages of healthcare staff, fluctuations in foreign currency exchange rates and volatility in capital markets may continue to affect IDEXX’s results of operations. These challenges, along with geopolitical instability, including the current war in Ukraine, have affected IDEXX’s supply chain operations globally. With sustained inflationary pressure in the future, the company may struggle to keep in check its cost of revenues and operating expenses.During the first quarter of 2024, IDEXX saw a significant 31.3% uptick in general and administrative expenses. Further, U.S. clinical visit growth levels in the first quarter were relatively softer than anticipated, which is likely due to the ongoing staffing challenges at veterinary clinics and broader cumulative macroeconomic pressure on U.S. consumers. Further, the majority of IDEXX's consolidated revenues are from product sales in international markets, with approximately 21% of total revenues in 2023 derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies. Thus, the strengthening of the rate of exchange for the U.S. dollar relative to other currencies had a negative impact on the company’s revenues derived in currencies other than the U.S. dollar and on profits from products manufactured in the United States and sold internationally. In 2023, foreign exchange reduced operating profits by $25 million (operating margin gains by 60 basis points) and EPS by 24 cents per share.During the first quarter of 2024, it had a limited impact on gross margin, operating profit and EPS. IDEXX’s updated 2024 revenue forecast includes a $35 million impact, equivalent to about a 1% decrease, due to the recent appreciation of the U.S. dollar.IDEXX Laboratories, Inc. Price IDEXX Laboratories, Inc. price | IDEXX Laboratories, Inc. QuoteHowever, IDEXX is focused on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. In late 2023, the company expanded its operations in the United States for the first time in four years, complementing the seven international expansions it has advanced since 2021. Through these strategic investments, the company continues to strengthen its growth prospects by delivering high-touch commercial engagement in the fastest-growing regions while maintaining strong business performance. This expanded global commercial capability is yielding strong results overseas, with notable 12% organic growth in international CAG diagnostic recurring revenues in the first quarter of 2024. Diagnostics has been one of the fastest-growing areas of the veterinary clinic for IDEXX since the determination of a patient's health status and the best treatment path often requires testing. IDEXX largely provides advanced diagnostic capabilities that meet veterinarians’ diverse needs through a variety of modalities, including in-clinic diagnostic solutions and outside reference laboratory services. These diagnostic capabilities generate a mix of recurring and non-recurring revenues.Key PicksSome better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS - Free Report) , High Tide (HITI Quick QuoteHITI - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) . Each of them sports a Zacks Rank #1 (Strong Buy) at present. Hims & Hers Heath stock has rallied 53.3% in the past year. Earnings estimates for the company have risen from 10 cents to 18 cents in 2024 and from 23 cents to 32 cents in 2025 in the past 30 days.HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.Estimates for High Tide’s 2024 earnings per share have remained unchanged in the past 30 days. Shares of the company have surged 57.9% upward in the past year against the industry’s fall of 0.6%.HITI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 91.7%. In the last reported quarter, it delivered an earnings surprise of 100%.Estimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $10.53 in the past 30 days. Shares of the company have risen 87.6% in the past year compared with the industry’s 5% growth.MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
IDEXX Laboratories' (IDXX Quick QuoteIDXX - Free Report) business has been suffering due to complex macroeconomic conditions and unfavorable currency movement. The stock carries a Zacks Rank #4 (Sell) currently.Global macroeconomic conditions, including growing geopolitical complexities, supply chain disruptions leading to increases in the unit cost of raw materials, shortages of healthcare staff, fluctuations in foreign currency exchange rates and volatility in capital markets may continue to affect IDEXX’s results of operations. These challenges, along with geopolitical instability, including the current war in Ukraine, have affected IDEXX’s supply chain operations globally. With sustained inflationary pressure in the future, the company may struggle to keep in check its cost of revenues and operating expenses.During the first quarter of 2024, IDEXX saw a significant 31.3% uptick in general and administrative expenses. Further, U.S. clinical visit growth levels in the first quarter were relatively softer than anticipated, which is likely due to the ongoing staffing challenges at veterinary clinics and broader cumulative macroeconomic pressure on U.S. consumers. Further, the majority of IDEXX's consolidated revenues are from product sales in international markets, with approximately 21% of total revenues in 2023 derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies. Thus, the strengthening of the rate of exchange for the U.S. dollar relative to other currencies had a negative impact on the company’s revenues derived in currencies other than the U.S. dollar and on profits from products manufactured in the United States and sold internationally. In 2023, foreign exchange reduced operating profits by $25 million (operating margin gains by 60 basis points) and EPS by 24 cents per share.During the first quarter of 2024, it had a limited impact on gross margin, operating profit and EPS. IDEXX’s updated 2024 revenue forecast includes a $35 million impact, equivalent to about a 1% decrease, due to the recent appreciation of the U.S. dollar.IDEXX Laboratories, Inc. Price IDEXX Laboratories, Inc. price | IDEXX Laboratories, Inc. QuoteHowever, IDEXX is focused on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. In late 2023, the company expanded its operations in the United States for the first time in four years, complementing the seven international expansions it has advanced since 2021. Through these strategic investments, the company continues to strengthen its growth prospects by delivering high-touch commercial engagement in the fastest-growing regions while maintaining strong business performance. This expanded global commercial capability is yielding strong results overseas, with notable 12% organic growth in international CAG diagnostic recurring revenues in the first quarter of 2024. Diagnostics has been one of the fastest-growing areas of the veterinary clinic for IDEXX since the determination of a patient's health status and the best treatment path often requires testing. IDEXX largely provides advanced diagnostic capabilities that meet veterinarians’ diverse needs through a variety of modalities, including in-clinic diagnostic solutions and outside reference laboratory services. These diagnostic capabilities generate a mix of recurring and non-recurring revenues.Key PicksSome better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS - Free Report) , High Tide (HITI Quick QuoteHITI - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) . Each of them sports a Zacks Rank #1 (Strong Buy) at present. Hims & Hers Heath stock has rallied 53.3% in the past year. Earnings estimates for the company have risen from 10 cents to 18 cents in 2024 and from 23 cents to 32 cents in 2025 in the past 30 days.HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.Estimates for High Tide’s 2024 earnings per share have remained unchanged in the past 30 days. Shares of the company have surged 57.9% upward in the past year against the industry’s fall of 0.6%.HITI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 91.7%. In the last reported quarter, it delivered an earnings surprise of 100%.Estimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $10.53 in the past 30 days. Shares of the company have risen 87.6% in the past year compared with the industry’s 5% growth.MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
05/14 14:00 EST - businesswire.com
IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation.
IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation.
05/01 14:31 EST - investorplace.com
Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI
Fortune.com recently reported that artificial intelligence (AI) is helping the pet care industry cope with a chronic veterinary shortage. AI use cases could become far more prevalent for pets than humans in the near term due to fewer impediments such as privacy laws.
Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI
Fortune.com recently reported that artificial intelligence (AI) is helping the pet care industry cope with a chronic veterinary shortage. AI use cases could become far more prevalent for pets than humans in the near term due to fewer impediments such as privacy laws.
05/01 11:46 EST - zacks.com
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.
05/01 10:35 EST - zacks.com
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/01 08:41 EST - zacks.com
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.68 per share. This compares to earnings of $2.55 per share a year ago.
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.68 per share. This compares to earnings of $2.55 per share a year ago.
05/01 08:19 EST - reuters.com
IDEXX Labs cuts 2024 revenue forecast on lagging vet visits, strong dollar
IDEXX Laboratories lowered its annual sales forecast after missing quarterly estimates on Wednesday, as the animal diagnostic equipment maker expects a hit from a slowdown in veterinary clinic visits by pet owners and a stronger dollar.
IDEXX Labs cuts 2024 revenue forecast on lagging vet visits, strong dollar
IDEXX Laboratories lowered its annual sales forecast after missing quarterly estimates on Wednesday, as the animal diagnostic equipment maker expects a hit from a slowdown in veterinary clinic visits by pet owners and a stronger dollar.
05/01 06:30 EST - businesswire.com
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and organic, and Water revenue growth of 11% as reported and organic. Overall IDEXX revenue gains were net of an estimated 0.5% - 1.
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and organic, and Water revenue growth of 11% as reported and organic. Overall IDEXX revenue gains were net of an estimated 0.5% - 1.
04/30 17:14 EST - youtube.com
How to trade Fed news, plus stocks to consider
The Federal Reserve has entered a two-day meeting that will end with an announcement about its decision regarding interest rates. In the meantime, debate on Wall Street has been raging over how, when, and if the Fed will raise rates.
How to trade Fed news, plus stocks to consider
The Federal Reserve has entered a two-day meeting that will end with an announcement about its decision regarding interest rates. In the meantime, debate on Wall Street has been raging over how, when, and if the Fed will raise rates.
04/26 10:21 EST - zacks.com
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
04/19 09:01 EST - zacks.com
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?
IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
04/18 12:41 EST - zacks.com
TMO vs. IDXX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Thermo Fisher Scientific (TMO) or Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better bang for their buck right now?
TMO vs. IDXX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Thermo Fisher Scientific (TMO) or Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better bang for their buck right now?
04/12 13:53 EST - investorplace.com
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
You may have heard about GPT-4 Turbo, Gemini, Llama or X's (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town.
New AI Bot Predicts These 7 Stocks Will Mint Millionaires
You may have heard about GPT-4 Turbo, Gemini, Llama or X's (formerly Twitter) Grok. However, there is a new contender outside of these Big Tech models in town.